Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Sees Significant Increase in Short Interest

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 619,061 shares, an increase of 125.8% from the January 15th total of 274,164 shares. Based on an average daily volume of 13,995,251 shares, the days-to-cover ratio is presently 0.0 days. Approximately 44.2% of the company’s shares are sold short. Approximately 44.2% of the company’s shares are sold short. Based on an average daily volume of 13,995,251 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

SHPH has been the topic of a number of analyst reports. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Shuttle Pharmaceuticals presently has an average rating of “Sell”.

Shuttle Pharmaceuticals Stock Up 7.8%

Shares of SHPH stock opened at $1.11 on Friday. The firm has a 50 day moving average of $1.77 and a 200-day moving average of $2.71. The company has a market cap of $1.78 million, a price-to-earnings ratio of -0.09 and a beta of -1.02. Shuttle Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $17.70.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share (EPS) for the quarter.

Institutional Trading of Shuttle Pharmaceuticals

An institutional investor recently bought a new position in Shuttle Pharmaceuticals stock. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,444 shares of the company’s stock, valued at approximately $26,000. Geode Capital Management LLC owned approximately 0.90% of Shuttle Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .